Nicholas J Graham

First FDA Approved Drug for PTCL on Market Now

I was interviewed by a New York Times reporter, Andy, about the recent release of the first FDA approved drug specifically indicated just for PTCL called FOLOTYNTM (pralatrexate injection) by Allos Therapeutics, Inc.

We spoke for 30 minutes and if the article is published, I will share it here.  Many thanks to Judy Jones of the Cutaneous Lymphoma Foundation for entrusting me to represent the PTCL patients that she knows.

Here is information about the release: http://www.medicalnewstoday.com/articles/165430.php.

It is wonderful news that we finally have an option now for our unique condition, although the rarity of our disease makes this therapy cost upwards of $9,000 a week!  I shared with the reporter that while it is obviously an exorbitant amount, I do understand enough of the nature of drug development (given my work at a medical education company) to appreciate the need recoup the cost on the R&D of a rare illnesses.  (Of course it would be nice to have it much more affordable, but only time will tell).